Alteri E - Search Results

1

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

Francis GS, Grumser Y, Alteri E, Micaleff A, O'Brien F, Alsop J, Stam Moraga M, Kaplowitz N. Francis GS, et al. Among authors: alteri e. Drug Saf. 2003;26(11):815-27. doi: 10.2165/00002018-200326110-00006. Drug Saf. 2003. PMID: 12908850 Clinical Trial.

2

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.

Rieckmann P, O'Connor P, Francis GS, Wetherill G, Alteri E. Rieckmann P, et al. Among authors: alteri e. Drug Saf. 2004;27(10):745-56. doi: 10.2165/00002018-200427100-00005. Drug Saf. 2004. PMID: 15350158

3

Liver injury associated with the beta-interferons for MS.

Francis GS, Kaplowitz N, Alteri E. Francis GS, et al. Among authors: alteri e. Neurology. 2004 Sep 28;63(6):1142-3; author reply 1142-3. Neurology. 2004. PMID: 15457586 No abstract available.

4

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.

Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Sandberg-Wollheim M, et al. Among authors: alteri e. Mult Scler. 2011 Apr;17(4):423-30. doi: 10.1177/1352458510394610. Epub 2011 Jan 10. Mult Scler. 2011. PMID: 21220368 Free article.

5

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.

Sandberg-Wollheim M, Kornmann G, Bischof D, Moraga MS, Hennessy B, Alteri E. Sandberg-Wollheim M, et al. Among authors: alteri e. Mult Scler. 2011 Apr;17(4):431-40. doi: 10.1177/1352458511403642. Mult Scler. 2011. PMID: 21486902 Free article.

6

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E. Mazzaglia G, et al. Among authors: alteri e. Drug Saf. 2018 Feb;41(2):191-202. doi: 10.1007/s40264-017-0604-4. Drug Saf. 2018. PMID: 29124666 Free PMC article.

7

Benznidazole in Chagas disease study: do the data justify progression to phase 3?

Alteri E. Alteri E. Lancet Infect Dis. 2021 Aug;21(8):1066-1067. doi: 10.1016/S1473-3099(21)00320-0. Lancet Infect Dis. 2021. PMID: 34331878 No abstract available.

8

Be open about drug failures to speed up research.

Alteri E, Guizzaro L. Alteri E, et al. Nature. 2018 Nov;563(7731):317-319. doi: 10.1038/d41586-018-07352-7. Nature. 2018. PMID: 30425369 No abstract available.

9

Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.

Butlen-Ducuing F, Pétavy F, Guizzaro L, Zienowicz M, Haas M, Alteri E, Salmonson T, Corruble E. Butlen-Ducuing F, et al. Among authors: alteri e. Nat Rev Drug Discov. 2016 Nov 29;15(12):813-814. doi: 10.1038/nrd.2016.237. Nat Rev Drug Discov. 2016. PMID: 27895328 No abstract available.

10

Anti-HIV-1 activity in vitro of ceftazidime degradation products.

Hobi R, Hübscher U, Neftel K, Alteri E, Poncioni B, Walker MR, Woods-Cook K, Schneider P, Lazdins JK. Hobi R, et al. Among authors: alteri e. Antivir Chem Chemother. 2001 Mar;12(2):109-18. doi: 10.1177/095632020101200204. Antivir Chem Chemother. 2001. PMID: 11527042 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters